TNGX Tango Therapeutics, Inc. Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
17:50
Aug 26
Aug 26
TNGX dismissed as junk investment
Author explicitly dismisses TNGX as being in the junk pile, a bearish do-not-own view without an explicit short position.
MED
11:32
Aug 18
Aug 18
JPMorgan, TD Cowen, Citigroup, Jefferies, and other firms raised price targets on twelve stocks.
JPMorgan, TD Cowen, Citigroup, Jefferies, and other firms raised price targets on twelve stocks while cutting targets on six others and initiating or resuming coverage on six additional names.
13:09
Aug 17
Aug 17
Author shares a net conviction chart listing multiple biotech tickers without explicit position.
Author shares a net conviction chart listing multiple biotech tickers without explicit position language, so these are indexed as watch rather than directional calls.
LOW
12:49
Aug 17
Aug 17
Reports most added positions across funds
"Reports most added positions across specialist funds from Q1 to Q2 2026, no directional view."
MED
11:50
Aug 17
Aug 17
Reports most added positions by specialist funds
Reports the most added positions by specialist funds from Q1 to Q2 2026.
MED
11:44
Jun 26
Jun 26
Premarket movers report shows mixed Mag 7 performance, semiconductor declines.
Premarket movers report shows mixed Mag 7 performance, semiconductor declines, ON Semiconductor sliding 14% on Synaptics deal, and gains in Rocket Lab, Tango Therapeutics, and Wise.
11:44
Jun 26
Jun 26
Premarket movers show mixed Mag 7 performance with semiconductor stocks broadly lower on demand.
Premarket movers show mixed Mag 7 performance with semiconductor stocks broadly lower on demand concerns, while ON Semiconductor slides 14% on Synaptics deal, Rocket Lab gains on NASA contract, Tango Therapeutics rises on Jefferies upgrade, and Wise climbs on buyback news.
13:13
Jun 21
Jun 21
Buy ERAS and TNGX as explicit M&A candidates in the RAS/oncology space.
Buy ERAS and TNGX as explicit M&A candidates in the RAS/oncology space; author identifies them as "in play" given the current wave of radiopharmaceutical and oncology deal activity, with ERAS at ~5.2 months post positive data squarely in the historical acquisition window.
MED
01:44
Jun 13
Jun 13
The author maps out M&A scenarios in oncology but presents them as possibilities and research.
The author maps out M&A scenarios in oncology but presents them as possibilities and research, not current positions or explicit trade calls.
LOW
23:23
Jun 12
Jun 12
Buy TNGX as both the data catalyst (pan-RAS(ON) + PRMT5 combination validation) and a potential.
Buy TNGX as both the data catalyst (pan-RAS(ON) + PRMT5 combination validation) and a potential acquisition target; author sees MRK as a possible acquirer of TNGX paired with ERAS in back-to-back deals.
MED
14:52
Jun 08
Jun 08
Tango shares surged as much as 48% after early study results showed its drug combined.
Tango shares surged as much as 48% after early study results showed its drug combined with a Revolution Medicine treatment shrank tumors in advanced pancreatic cancer patients.
About TNGX Analyst Coverage
Buzzberg tracks TNGX (Tango Therapeutics, Inc.) across 4 sources. 2 bullish vs 0 bearish calls from 4 analysts. Sentiment: predominantly bullish (18%). 11 total trade ideas tracked. Latest voices: seedy19tron, DeItaone, zerohedge.